Plus   Neg

Genentech Says Perjeta Combination Increased Survival In Breast Cancer Patients

Genentech, a member of the Roche Group (RHHBY), Friday said new data from a late-stage study showed combining its breast cancer drug Perjeta with another combination significantly improved overall survival in patients.

The company noted that people with HER2-positive metastatic breast cancer, or mBC, lived significantly longer when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone.

Hal Barron, chief medical officer and head, Global Product Development stated, "We are pleased that Perjeta helped people with HER2-positive metastatic breast cancer live longer and lengthened the time they lived without their disease worsening."

Perjeta is a personalized medicine that targets the HER2 receptor - a protein found in high quantities on the outside of cancer cells in HER2-positive cancers.

Genentech said the median progression-free survival improved by 6.1 months from 12.4 months for people who received Herceptin and chemotherapy plus placebo to 18.5 months for those who received Perjeta, Herceptin and chemotherapy.

The FDA recently approved Perjeta in combination with Herceptin and docetaxel chemotherapy to treat people who have not received prior anti-HER2 therapy. Roche has submitted a marketing authorization application to the European Medicines Agency for Perjeta for people with previously untreated HER2-positive mBC.

The international, Phase III, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety profile of Perjeta combined with Herceptin and docetaxel chemotherapy in 808 people.

Genentech said it will submit these data for presentation at an upcoming medical meeting.

RHHBY closed Thursday's regular trading at $42.01.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Canada-based cannabis company Cronos Group Inc. (CRON) and MM Enterprises USA LLC said Monday that they have formed a cross-border joint venture to cater to Canadian consumers. The move comes as Canada plans to legalize adult use of cannabis by the end of this year. MM Enterprises USA, LLC is a U.S. cannabis company with facilities in California, Nevada, and New York. Qualcomm Inc.'s former Chairman Paul Jacobs plans to acquire the chipmaker founded by his father and has approached several global investors in an effort to fund the buyout, the Financial Times reported. According to the report, Jacobs informed members of the Qualcomm board about his intention to take the company private. Qualcomm has a market capitalization of $90 billion. Tiffany & Co. (TIF) reported fourth-quarter net earnings of $62 million, or $0.50 per diluted share, which were 61% below the prior year's $158 million, or $1.26 per diluted share. The company recorded tax-related charges in the fourth quarter of 2017 and certain impairment charges in last year's fourth...
comments powered by Disqus
Follow RTT